Soliqua 100/33 mechanism of action?

Soliqua 100/33 is a ready‑to‑inject, single‑dose premixed insulin that contains two different insulin analogs in a 100:33 unit ratio:

How the two insulins work together

1. Basal coverage (glargine)
   Glargine is an analog of human insulin that has a slightly acidic formulation (pH ≈ 4). When injected into the subcutaneous tissue it precipitates, creating a depot that slowly dissolves and releases insulin over ~24 h.

   • The slow release mimics the body’s normal basal insulin secretion, keeping fasting and overnight glucose levels in check.

2. Prandial coverage (aspart)
   Aspart has a proline‑to‑aspartate substitution at position 28 on the B‑chain, which prevents it from forming hexamers in solution. This keeps it in a monomeric state, allowing it to be absorbed quickly into circulation.

   • It spikes in the bloodstream within minutes of injection, peaking at about 30–90 minutes and then declines, covering the post‑meal glucose rise.

3. Combined effect

   • The 100:33 ratio means that for every 100 units of basal insulin you get roughly 33 units of rapid‑acting insulin.
   • In practice, this delivers a basal‑bolus insulin regimen in a single injection: the long‑acting portion handles basal needs and the rapid‑acting portion tackles meal‑time spikes.

Mechanism at the cellular level

Both insulins bind to the insulin receptor tyrosine kinase on target cells (muscle, adipose, liver). This triggers:

1. Receptor autophosphorylation → activation of downstream signaling pathways (PI3K/Akt, MAPK).
2. GLUT4 translocation to the cell surface → increased glucose uptake into cells, lowering blood glucose.
3. Inhibition of hepatic gluconeogenesis and stimulation of glycogen synthesis.

Because the two components of Soliqua act on the same receptor but with different kinetics, they together provide comprehensive glycaemic control without the need for separate basal and prandial injections.

Practical notes

• Administration: Subcutaneous injection, usually once daily (often in the evening) or twice daily, depending on the patient’s insulin needs.
• Flexibility: The rapid‑acting part can be given 10–15 minutes before a meal; the basal part continues to provide steady coverage.
• Monitoring: Blood glucose monitoring remains essential to adjust doses, as the fixed ratio may not suit every individual’s fasting versus post‑meal needs.

Bottom line

Soliqua 100/33 delivers a basal insulin (glargine) that provides continuous 24‑hour coverage and a bolus insulin (aspart) that acts quickly after meals. The combination mimics the natural basal–bolus pattern of insulin secretion, helping people with type 2 diabetes manage fasting and post‑prandial glucose levels with a single injection.